A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer.

PLoS One · 2016 · PMC4938513 · PMID 27390847

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While this trial’s results were formally negative, as the improvement in OS did not reach statistical significance, it did show improved response rate and progression free survival (PFS) in the investigational arm, and a potential impact of bevacizumab in this disease was not excluded.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.